Table 2 Baseline and cycle characteristics in DOR patients undergoing blastocyst culture.
Viable blastocyst | Nonviable blastocyst | P | |
|---|---|---|---|
Number | 275 | 97 | |
Cycle | 280 | 99 | |
Age (years) | 33.7 ± 4.51 | 35.57 ± 5.15 | 0.002* |
Duration of infertility (year) | 3.1 ± 2.83 | 3.34 ± 3.16 | 0.838 |
Type of infertility (%) (1/2) | 0.218 | ||
Primary infertility (1) | 138 (49.29) | 41 (41.41) | |
Secondary infertility (2) | 142 (50.71) | 58 (58.59) | |
Cause of infertility (%) (1/2/3/4) | 0.673 | ||
Female factor (1) | 232 (82.86) | 85 (85.86) | |
Male factor (2) | 2 (0.71) | 0 (0) | |
Mixed factor (3) | 45 (16.07) | 14 (14.14) | |
Unexplained factor (4) | 1 (0.36) | 0 (0) | |
Anti-Mullerian hormone (ng/ml) | 0.8 ± 0.46 | 0.72 ± 0.3 | 0.268 |
Antral follicle count | 4.56 ± 1.7 | 4.31 ± 1.8 | 0.278 |
Basal follicle-stimulating hormone (IU/L) | 10.0 ± 3.51 | 10.92 ± 5.26 | 0.220 |
Basal luteinizing hormone (IU/L) | 3.6 ± 1.54 | 3.45 ± 1.95 | 0.166 |
Basal estradiol (pg/ml) | 43.76 ± 24.31 | 41.5 ± 21.89 | 0.147 |
Basal progesterone (ng/ml) | 0.62 ± 0.44 | 0.57 ± 0.25 | 0.638 |
Body-mass index (kg/m2) | 21.83 ± 2.92 | 22.63 ± 3.29 | 0.029* |
Controlled ovarian stimulation protocol (%) (1/2/3/4/5) | 0.096 | ||
GnRH antagonist protocol (1) | 222 (79.29) | 64 (64.65) | |
GnRH-agonist long protocol (2) | 6 (2.14) | 1 (1.01) | |
Mild stimulation protocol (3) | 17 (6.07) | 12 (12.12) | |
Progestin-primed ovarian stimulation protocol (4) | 35 (12.5) | 17 (17.17) | |
Natural cycle (5) | 0 (0) | 0 (0) | |
Initial gonadotropin doses (IU) | 267.41 ± 50.87 | 257.83 ± 60.68 | 0.237 |
Total gonadotropin dose (IU) | 2565.27 ± 671.62 | 2517.42 ± 925.42 | 0.285 |
Duration of stimulation days (d) | 9.85 ± 1.8 | 9.63 ± 2.16 | 0.237 |
Trigger day E2 value (pg/ml) | 1600.94 ± 831.6 | 1321.58 ± 698.52 | 0.004* |
Trigger day P value (ng/ml) | 0.9 ± 0.74 | 0.88 ± 0.98 | 0.157 |
Trigger day LH value (IU/L) | 3.0 ± 2.66 | 3.75 ± 3.24 | 0.030* |
No. of retrieved oocytes | 5.56 ± 2.3 | 4.23 ± 1.71 | < 0.001* |
No. of mature (MII) oocytes | 4.97 ± 2.07 | 3.68 ± 1.32 | < 0.001* |
No. of 2PN embryos | 3.98 ± 1.7 | 2.65 ± 1.28 | < 0.001* |
No. of normal cleavage embryos | 3.94 ± 1.66 | 2.62 ± 1.29 | < 0.001* |
No. of D3-available cleavage-stage embryos | 3.97 ± 1.4 | 2.87 ± 1.03 | < 0.001* |
No. of D3 top-quality cleavage-stage embryos | 2.15 ± 1.3 | 1.35 ± 1.02 | < 0.001* |
MII oocyte rate (%) | 1392/1556 (89.46) | 364/419 (86.87) | 0.920 |
2PN rate (%) | 1114/1556 (71.59) | 262/419 (62.53) | 0.013* |
D3 top-quality cleavage stage-embryo rate (%) | 601/1316 (45.67) | 134/331 (40.48) | 0.039* |
